Paul Josephs Purchases 17,000 Shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) Stock

Lifecore Biomedical, Inc. (NASDAQ:LFCR - Get Free Report) CEO Paul Josephs acquired 17,000 shares of the firm's stock in a transaction on Wednesday, January 8th. The shares were bought at an average cost of $5.74 per share, with a total value of $97,580.00. Following the completion of the acquisition, the chief executive officer now directly owns 559,717 shares in the company, valued at approximately $3,212,775.58. This represents a 3.13 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Lifecore Biomedical Stock Performance

Shares of LFCR stock traded down $0.11 during trading on Wednesday, hitting $5.80. The company's stock had a trading volume of 376,679 shares, compared to its average volume of 657,135. The company has a current ratio of 1.83, a quick ratio of 0.80 and a debt-to-equity ratio of 12.90. The company has a market cap of $213.60 million, a PE ratio of 72.50 and a beta of 0.98. The business has a fifty day moving average of $7.05 and a 200-day moving average of $5.82. Lifecore Biomedical, Inc. has a 52 week low of $3.68 and a 52 week high of $8.90.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last announced its quarterly earnings data on Thursday, January 2nd. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.02. Lifecore Biomedical had a negative return on equity of 382.65% and a net margin of 5.09%. As a group, research analysts anticipate that Lifecore Biomedical, Inc. will post -0.99 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on LFCR shares. Stephens restated an "equal weight" rating and set a $6.00 price objective on shares of Lifecore Biomedical in a research note on Friday, January 3rd. Craig Hallum increased their target price on shares of Lifecore Biomedical from $8.00 to $10.00 and gave the company a "buy" rating in a report on Friday, November 22nd.

Institutional Trading of Lifecore Biomedical

A number of large investors have recently added to or reduced their stakes in LFCR. Bank of New York Mellon Corp purchased a new position in Lifecore Biomedical in the second quarter valued at about $327,000. Rhumbline Advisers raised its holdings in shares of Lifecore Biomedical by 1,668.5% in the 2nd quarter. Rhumbline Advisers now owns 26,899 shares of the company's stock worth $138,000 after purchasing an additional 25,378 shares during the period. Renaissance Technologies LLC purchased a new position in Lifecore Biomedical in the second quarter valued at approximately $56,000. DCF Advisers LLC grew its holdings in Lifecore Biomedical by 2.1% during the second quarter. DCF Advisers LLC now owns 290,684 shares of the company's stock valued at $1,491,000 after purchasing an additional 6,000 shares during the period. Finally, Marshall Wace LLP increased its position in Lifecore Biomedical by 87.3% in the second quarter. Marshall Wace LLP now owns 300,120 shares of the company's stock worth $1,540,000 after buying an additional 139,887 shares during the last quarter. Hedge funds and other institutional investors own 83.36% of the company's stock.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.